Absolute Lymphocyte Count as a Marker for Cytomegalovirus Infection After Heart Transplantation.
Journal
Transplantation
ISSN: 1534-6080
Titre abrégé: Transplantation
Pays: United States
ID NLM: 0132144
Informations de publication
Date de publication:
01 03 2023
01 03 2023
Historique:
pubmed:
14
10
2022
medline:
25
2
2023
entrez:
13
10
2022
Statut:
ppublish
Résumé
Previous studies indicate an association between reduced absolute lymphocyte count (ALC) and cytomegalovirus (CMV) infection after solid organ transplantation and have therefore highlighted the potential of ALC as a simple tool to predict CMV infection in transplant patients. This study aimed to examine the utility of ALC as a valuable marker for CMV infection in heart transplant patients. Clinical information and ALC data of all adult patients who received orthotopic heart transplantation at the Medical University of Vienna between January 2004 and May 2019 were collected. We performed a multivariable Cox regression model that incorporates repeated measurements of ALC as a time-varying continuous factor in 2 ways, first as continuous logarithmic factor considering a 50% decrease of ALC levels and second as binary factor using a threshold of 610 cells/μL. One hundred fifty-eight (39%) patients developed CMV infection over the course of 2 y. Patients with lymphopenia were shown to be at higher risk of developing CMV infection both in the continuous approach (HR [per 50% reduction] 1.29; confidence interval [CI], 1.09-1.53; P = 0.003) and the binary approach with a cutoff of 610 cells/μL (HR 1.74; CI, 1.20-2.51; P = 0.003). This study demonstrated a strong association between reduced ALC and the development of CMV infection after heart transplantation. ALC value monitoring could provide an additional tool to assess individualized CMV risk after solid organ transplantation.
Sections du résumé
BACKGROUND
Previous studies indicate an association between reduced absolute lymphocyte count (ALC) and cytomegalovirus (CMV) infection after solid organ transplantation and have therefore highlighted the potential of ALC as a simple tool to predict CMV infection in transplant patients. This study aimed to examine the utility of ALC as a valuable marker for CMV infection in heart transplant patients.
METHODS
Clinical information and ALC data of all adult patients who received orthotopic heart transplantation at the Medical University of Vienna between January 2004 and May 2019 were collected. We performed a multivariable Cox regression model that incorporates repeated measurements of ALC as a time-varying continuous factor in 2 ways, first as continuous logarithmic factor considering a 50% decrease of ALC levels and second as binary factor using a threshold of 610 cells/μL.
RESULTS
One hundred fifty-eight (39%) patients developed CMV infection over the course of 2 y. Patients with lymphopenia were shown to be at higher risk of developing CMV infection both in the continuous approach (HR [per 50% reduction] 1.29; confidence interval [CI], 1.09-1.53; P = 0.003) and the binary approach with a cutoff of 610 cells/μL (HR 1.74; CI, 1.20-2.51; P = 0.003).
CONCLUSIONS
This study demonstrated a strong association between reduced ALC and the development of CMV infection after heart transplantation. ALC value monitoring could provide an additional tool to assess individualized CMV risk after solid organ transplantation.
Identifiants
pubmed: 36228318
doi: 10.1097/TP.0000000000004360
pii: 00007890-202303000-00030
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
748-752Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors declare no funding or conflicts of interest.
Références
Sinnott JT, Cancio MR. Cytomegalovirus. Infect Control. 1987;8:79–82.
Rubin RH. Impact of cytomegalovirus infection on organ transplant recipients. Rev Infect Dis. 1990;12 Suppl 7:S754–S766.
Snydman DR, Limaye AP, Potena L, et al. Update and review: state-of-the-art management of cytomegalovirus infection and disease following thoracic organ transplantation. Transplant Proc. 2011;43:S1–S17.
Chemaly RF, Chou S, Einsele H, et al.; Resistant Definitions Working Group of the Cytomegalovirus Drug Development Forum. Definitions of resistant and refractory cytomegalovirus infection and disease in transplant recipients for use in clinical trials. Clin Infect Dis. 2019;68:1420–1426.
Valantine H. Cardiac allograft vasculopathy after heart transplantation: risk factors and management. J Heart Lung Transplant. 2004;23:S187–S193.
Potena L, Valantine HA. Cytomegalovirus-associated allograft rejection in heart transplant patients. Curr Opin Infect Dis. 2007;20:425–431.
Desai R, Collett D, Watson CJ, et al. Impact of cytomegalovirus on long-term mortality and cancer risk after organ transplantation. Transplantation. 2015;99:1989–1994.
Suarez-Pierre A, Giuliano K, Lui C, et al. Impact of cytomegalovirus serologic status on heart transplantation. J Card Surg. 2020;35:1431–1438.
Goekler J, Zuckermann A, Kaider A, et al. Diminished impact of cytomegalovirus infection on graft vasculopathy development in the antiviral prophylaxis era - a retrospective study. Transpl Int. 2018;31:909–916.
El Helou G, Lahr B, Razonable R. Absolute lymphocyte count as marker of cytomegalovirus and allograft rejection: Is there a “Safe Corridor” after kidney transplantation? Transpl Infect Dis. 2021;23:e13489.
Meesing A, Razonable RR. Absolute lymphocyte count thresholds: a simple, readily available tool to predict the risk of cytomegalovirus infection after transplantation. Open Forum Infect Dis. 2018;5:ofy230.
Gardiner BJ, Nierenberg NE, Chow JK, et al. Absolute lymphocyte count: a predictor of recurrent cytomegalovirus disease in solid organ transplant recipients. Clin Infect Dis. 2018;67:1395–1402.
Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin Pharmacokinet. 2007;46:13–58.
Mohty M. Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond. Leukemia. 2007;21:1387–1394.
Razonable RR, Hayden RT. Clinical utility of viral load in management of cytomegalovirus infection after solid organ transplantation. Clin Microbiol Rev. 2013;26:703–727.
Durlik M, Siennicka J, Litwińska B, et al. Clinical manifestations and diagnosis of cytomegalovirus infection in renal allograft recipients. Transplant Proc. 2001;33:1237–1239.
Kalil AC, Levitsky J, Lyden E, et al. Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med. 2005;143:870–880.
Fernández-Ruiz M, López-Medrano F, Allende LM, et al. Kinetics of peripheral blood lymphocyte subpopulations predicts the occurrence of opportunistic infection after kidney transplantation. Transpl Int. 2014;27:674–685.
Fernández-Ruiz M, López-Medrano F, Romo EM, et al. Pretransplant lymphocyte count predicts the incidence of infection during the first two years after liver transplantation: pretransplant lymphocyte count and infection. Liver Transpl. 2009;15:1209–1216.
Corona-Nakamura AL, Monteón-Ramos FJ, Troyo-Sanromán R, et al. Incidence and predictive factors for cytomegalovirus infection in renal transplant recipients. Transplant Proc. 2009;41:2412–2415.
Nierenberg NE, Poutsiaka DD, Chow JK, et al. Pretransplant lymphopenia is a novel prognostic factor in cytomegalovirus and noncytomegalovirus invasive infections after liver transplantation. Liver Transpl. 2014;20:1497–1507.
Meesing A, Abraham RS, Razonable RR. Clinical correlation of cytomegalovirus infection with CMV-specific CD8+ T-cell immune competence score and lymphocyte subsets in solid organ transplant recipients. Transplantation. 2019;103:832–838.
Pour-Reza-Gholi F, Labibi A, Farrokhi F, et al. Signs and symptoms of cytomegalovirus disease in kidney transplant recipients. Transplant Proc. 2005;37:3056–3058.